Literature DB >> 25270258

Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration.

Toby J Phesse1, Michael Buchert1, Emma Stuart1, Dustin J Flanagan2, Maree Faux1, Shoukat Afshar-Sterle1, Francesca Walker1, Hui-Hua Zhang1, Cameron J Nowell1, Robert Jorissen1, Chin Wee Tan1, Yumiko Hirokawa1, Moritz F Eissmann1, Ashleigh R Poh1, Jordane Malaterre3, Helen B Pearson3, David G Kirsch4, Paolo Provero5, Valeria Poli5, Robert G Ramsay3, Oliver Sieber1, Antony W Burgess1, Dennis Huszar6, Elizabeth Vincan2, Matthias Ernst7.   

Abstract

Most colon cancers arise from somatic mutations in the tumor suppressor gene APC (adenomatous polyposis coli), and these mutations cause constitutive activation of the Wnt-to-β-catenin pathway in the intestinal epithelium. Because Wnt-β-catenin signaling is required for homeostasis and regeneration of the adult intestinal epithelium, therapeutic targeting of this pathway is challenging. We found that genetic activation of the cytokine-stimulated pathway mediated by the receptor gp130, the associated Jak (Janus kinase) kinases, and the transcription factor Stat3 (signal transducer and activator of transcription 3) was required for intestinal regeneration in response to irradiation-induced damage in wild-type mice and for tumorigenesis in Apc-mutant mice. Systemic pharmacological or partial genetic inhibition of gp130-Jak-Stat3 signaling suppressed intestinal regeneration, the growth of tumors in Apc-mutant mice, and the growth of colon cancer xenografts. The growth of Apc-mutant tumors depended on gp130-Jak-Stat3 signaling for induction of the polycomb repressor Bmi-1, and the associated repression of genes encoding the cell cycle inhibitors p16 and p21. However, suppression of gp130-Jak-Stat3 signaling did not affect Wnt-β-catenin signaling or homeostasis in the intestine. Thus, these data not only suggest a molecular mechanism for how the gp130-Jak-Stat3 pathway can promote cancer but also provide a rationale for therapeutic inhibition of Jak in colon cancer.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270258     DOI: 10.1126/scisignal.2005411

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  32 in total

1.  Reg3g Promotes Pancreatic Carcinogenesis in a Murine Model of Chronic Pancreatitis.

Authors:  Guoxiao Yin; Jiao Du; Hui Cao; Xiulan Liu; Qianqian Xu; Ming Xiang
Journal:  Dig Dis Sci       Date:  2015-07-17       Impact factor: 3.199

2.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Authors:  Herbert I Hurwitz; Nikhil Uppal; Stephanie A Wagner; Johanna C Bendell; J Thaddeus Beck; Seaborn M Wade; John J Nemunaitis; Philip J Stella; J Marc Pipas; Zev A Wainberg; Robert Manges; William M Garrett; Deborah S Hunter; Jason Clark; Lance Leopold; Victor Sandor; Richard S Levy
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.

Authors:  Xiaojuan Wu; Yang Cao; Hui Xiao; Chenglong Li; Jiayuh Lin
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

Review 4.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Authors:  M Buchert; C J Burns; M Ernst
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

Review 5.  Chronic inflammation and the development of malignancy in the GI tract.

Authors:  Stefan Fichtner-Feigl; Rebecca Kesselring; Warren Strober
Journal:  Trends Immunol       Date:  2015-07-18       Impact factor: 16.687

Review 6.  The potential role of liver stem cells in initiation of primary liver cancer.

Authors:  Xiao-Song Zhi; Jun Xiong; Xiao-Yuan Zi; Yi-Ping Hu
Journal:  Hepatol Int       Date:  2016-05-02       Impact factor: 6.047

Review 7.  Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models.

Authors:  Toby J Phesse; Victoria Marsh Durban; Owen J Sansom
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

8.  Inflammation and Colorectal Cancer.

Authors:  Apple G Long; Emma T Lundsmith; Kathryn E Hamilton
Journal:  Curr Colorectal Cancer Rep       Date:  2017-06-17

9.  Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Authors:  Carla S Milagre; Ganga Gopinathan; Gemma Everitt; Richard G Thompson; Hagen Kulbe; Haihong Zhong; Robert E Hollingsworth; Richard Grose; David D L Bowtell; Daniel Hochhauser; Frances R Balkwill
Journal:  Cancer Res       Date:  2015-02-10       Impact factor: 12.701

Review 10.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.